See more : Keppel Corporation Limited (BN4.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Fortrea Holdings Inc. (FTRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fortrea Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Comstock Metals Ltd. (CMMMF) Income Statement Analysis – Financial Results
- Canamera Energy Metals Corp. (EMET.CN) Income Statement Analysis – Financial Results
- Fabrica Communications Co., LTD. (4193.T) Income Statement Analysis – Financial Results
- Xinyi Solar Holdings Limited (0968.HK) Income Statement Analysis – Financial Results
- Intertek Group plc (IKTSF) Income Statement Analysis – Financial Results
Fortrea Holdings Inc. (FTRE)
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 3.11B | 3.10B | 3.06B | 2.58B |
Cost of Revenue | 2.69B | 2.47B | 2.45B | 2.09B |
Gross Profit | 424.00M | 621.70M | 604.40M | 489.10M |
Gross Profit Ratio | 13.64% | 20.08% | 19.77% | 18.96% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 336.60M | 299.90M | 303.10M | 267.60M |
Other Expenses | 0.00 | 7.00M | 1.90M | 800.00K |
Operating Expenses | 457.30M | 396.20M | 469.40M | 386.60M |
Cost & Expenses | 3.05B | 2.87B | 2.92B | 2.48B |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 69.80M | 132.40M | 200.00K | 0.00 |
Depreciation & Amortization | 96.40M | 117.60M | 198.80M | 156.40M |
EBITDA | 166.90M | 354.60M | 335.20M | -175.80M |
EBITDA Ratio | 5.37% | 10.62% | 9.87% | 25.46% |
Operating Income | 63.10M | 185.20M | 114.30M | -314.20M |
Operating Income Ratio | 2.03% | 5.98% | 3.74% | -12.18% |
Total Other Income/Expenses | -62.00M | 1.10M | 22.10M | -434.70M |
Income Before Tax | 1.10M | 58.90M | 136.40M | -332.20M |
Income Before Tax Ratio | 0.04% | 1.90% | 4.46% | -12.87% |
Income Tax Expense | 4.50M | 500.00K | 38.40M | 27.00M |
Net Income | -3.40M | 58.40M | 98.00M | -359.20M |
Net Income Ratio | -0.11% | 1.89% | 3.21% | -13.92% |
EPS | -0.04 | 0.66 | 1.11 | -4.06 |
EPS Diluted | -0.04 | 0.64 | 1.11 | -4.06 |
Weighted Avg Shares Out | 88.80M | 88.40M | 88.40M | 88.40M |
Weighted Avg Shares Out (Dil) | 88.80M | 91.10M | 88.40M | 88.40M |
Fortrea Appoints Machelle Sanders to Board of Directors
Fortrea Holdings (FTRE) Q1 2024 Earnings Call Transcript
Fortrea Reports First Quarter 2024 Results
Fortrea Reschedules Release of First Quarter 2024 Financial Results and Conference Call
Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call
Fortrea Holdings Inc. (FTRE) Q4 2023 Earnings Call Transcript
Fortrea sells enabling services and patient access businesses for up to $345 mln
Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Source: https://incomestatements.info
Category: Stock Reports